• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 9, 2016

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Scientists from the German Leibniz Institute for Experimental Virology and the Bernhard Nocht Institute for Tropical Medicine have discovered that T-cell dysregulation is an important facet of the immune system response to Ebola virus disease. Read More

In the clinic

Intarcia Therapeutics Inc., of Boston, said top-line results from its 4,000-plus-patient FREEDOM-CVO cardiovascular safety study showed it met all clinical endpoints. Read More

Other news to note

Recyte Therapeutics Inc., a subsidiary of Biotime Inc., both of Alameda, Calif., said a paper reporting the isolation of pericyte-like cells from human embryonic stem cells was published online in Scientific Reports. Recyte researchers said the pericyte-like cells represent a type of cell that is specialized to support and strengthen blood vessels. The pericytes may serve as a source of cells to promote new blood flow in patients suffering from ischemic vascular disease, according to the company. Read More

Appointments and advancements

Dicerna Pharmaceuticals Inc., of Cambridge, Mass., named John B. "Jack" Green as chief financial officer. Read More

Financings

Intellia Therapeutics Inc., of Cambridge, Mass., said it priced its IPO of 6 million shares of common stock at $18 per share for gross proceeds of $108 million. Read More

Earnings

PTC Therapeutics Inc., of South Plainfield, N.J., reported net sales of Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) totaling $18.9 million for the first quarter. Read More

Adcom hardly Apadaz'led by block-abuse properties; Kempharm circles wagons

Wall Street must wait for later this week to find out more from Kempharm Inc. about FDA talks ahead and further steps with Apadaz (KP201/APAP) for pain, but meanwhile an advisory panel's vote against the compound's abuse-deterrent properties sent shares (NASDAQ:KMPH) into a tailspin Friday to close at $6.91, down $8.76, or 55.9 percent. Read More

Post negative ODAC vote, Clovis scrubs rociletinib program, plans staff cuts

Anticipating an FDA complete response letter (CRL) for rociletinib, Clovis Oncology Inc. quit enrolling ongoing studies of the drug, withdrew its European marketing authorization application (MAA) filing and expects to trim its headcount by 35 percent from its 2015 level by year-end. In wake of the reckoning, Clovis is turning its full attention to potential approval and commercialization of its PARP 1-3 inhibitor, rucaparib. Read More

CRO Ergomed gains coagulant pipeline in Haemostatix buy

LONDON – Ergomed plc is branching out from its core business as a contract research organization (CRO) to acquire Haemostatix Ltd., a specialist in synthetic coagulants for use in surgery. Read More

New therapeutic target identified against glioblastoma

HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease. Read More

India's new biosimilar guidelines draw mixed reviews from pharma

NEW DELHI – India's revised draft guidelines for biosimilars have drawn mixed reactions. The country's pharma industry has, in broad strokes, welcomed the increased clarity and more rigorous conditions in the revised guidelines, but the Organisation of Pharmaceutical Producers of India, comprising largely foreign pharma firms, said the new rules could compromise patient safety. Read More

Peru's pharma guild evaluates guidelines for biosimilars

BOGOTA, Colombia – Less than two months after Peru issued technical standards to register and re-register biosimilars, the new regulations are generating buzz in the country's biopharma space. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe